On Dec. 25, 2019, Medigen Vaccine Biologics (MVB) announced it had completed the enrollment of phase III multi-region clinical trial for EV71 Vaccine. The total enrollment was over 3,000 subjects which met the target.

Enterovirus 71 (EV71) virus is one of the most prevalent infectious diseases in Taiwan, China and Southeast Asia. However, there are currently no vaccines available in these regions except China. Enterovirus 71 (EV71) is one of the main causative pathogens of hand, foot and mouth disease (HFMD).